Table. 2.

Metabolic effects on body weight, blood pressure, and glycemic control after one year of dapagliflozin treatment

Group ΔBWT (kg) ΔSBP (mmHg) ΔDBP (mmHg) ΔHbA1c (%) ΔPP2 (mg/dL) ΔFPG (mg/dL)
Total -3.4±2.6 -6.0±14 -3.4±7.7 -0.61±0.82 -35.4±62 -21.3±56.2
Group 1+2+3 P<0.001* P=0.001* P=0.002* P<0.001* P<0.001* P=0.012*
Group 1 -3.4±3.1 -6.0±16 -3.0±8.4 -0.39±0.80 -19.2±41.0 -16.0±33.3
 (Dual combination) P<0.001* P=0.146 P=0.109 P=0.093 P=0.152 P=0.088
Group 2 -2.7±2.0 -6.6±17.9 -5.8±9.3 -0.93±1.0 -63.1±90.6 -22.4±99.0
 (Triple combination) P=0.008* P=0.165 P=0.064 P=0.018* P=0.034* P=0.790
Group 3 -4.0±2.3 -5.1±10.0 -2.7±6.3 -0.65±0.71 -37.9±61.4 -24.8±42.4
 (Quadriple combination) P<0.001* P=0.013* P=0.092 P=0.002* P=0.001* P=0.039*

Values are presented as mean±standard deviation.

P<0.05.

Δ, difference between values before and after one year of treatment; BWT, body weight; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; PP2, post prandial plasma glucose 2 hours; FPG, fasting plasma glucose.

J Obes Metab Syndr 2017;26:107~113 https://doi.org/10.7570/jomes.2017.26.2.107
© JOMES